INTRODUCTION
Stimulation of ovarian follicular development is, at present, the most widely therapeutic modality used for treatment of the infertile couple. The introduction of hormonal and chemical agents designed to produce follicular development and ovulation represents one of the major advances in the field of reproductive endocrinology. Thus, ovulation induction has become one of the areas of the greatest success for the practicing reproductive endocrinologist. The advances that have occurred over the past recent years have resulted in a variety of techniques available to restore ovulatory cycles to infertile women with irregular menses or amenorrhea (1) . Ovulation-inducing drugs, however, are also being increasingly administered to normally ovulating women because of the high number of couples undergoing the different techniques that are used for assisted reproduction. The choice of ovarian stimulation technique depends on the individual circumstances of each particular woman, and appropriate patient selection is critical to achieving success.
The great majority of patients with anovulation falls into the World Health Organization (WHO) group II (2) category, and most of these women will present with polycystic ovary syndrome (PCOS). WHO group II anovulation is characterized by evidence of endogenous estrogen activity and a distinctive gonadotropin pattern revealing an elevated luteinizing hormone (LH) and normal or low follicle-stimulating hormone (FSH) output (3) . In these estrogenized patients, clomiphene citrate is the first-line treatment for ovulation induction. In clomiphene failures, injectable gonadotropins remain a successful alternative (1) . Several recent, large reports (4) (5) (6) (7) (8) , including a multicenter study in Spain (8) , have shown the safety and effectiveness of stepwise and low-dose administration of pure (pFSH) or highly purified FSH (HP-FSH) preparations for ovulation induction in WHO group II anovulatory women.
Gonadotropins are being used in two major groups of normal ovulatory women: women undergoing in vitro fertilization (IVF) and women receiving controlled ovarian hyperstimulation cycles in association with artificial insemination. In the latter group of patients we have previously reported the efficacy and safety of a late low-dose technique of administering pFSH for ovarian stimulation (9) .
All those previous reports included patients treated with urinary FSH (pFSH, HP-FSH) preparations. At present, recombinant FSH (rFSH) is being marketed in different countries throughout the world and it has recently become available in Spain. Very recently, the first clinical study carried out to compare rFSH with HP-FSH in IVF showed that both the dose of FSH and the number of days of treatment were significantly lower in the rFSH group than in the HP-FSH group (10) .
Therefore, the present study was undertaken to compare ovarian performance and hormonal levels, after ovarian stimulation, in both normally ovulating women and WHO group II anovulatory infertile patients, using rFSH and HP-FSH (the only urinary FSH preparation marketed in Spain), which, to our knowledge, has not been previously reported.
MATERIAL AND METHODS
In all, 40 primary infertility women were included in our study. Twenty of them (Group 1) were normally ovulatory women according to their regular menstrual pattern every 27-33 days, basal body temperature recording, midluteal plasma progesterone and prolactin determinations, timed premenstrual endometrial biopsy, and a mean basal (cycle days 2-4) LHrFSH ratio of 0.5 ± 0.1 on cycle days 2-4. They had normal ovarian morphology in vaginal ultrasonography. The mean age of patients in group 1 was 33 ± 2.1 years, and their mean duration of infertility was 4.5 ± 1.1 years. Each woman in group 1 had undergone two or three intrauterine insemination (IUI) cycles in association with ovarian gonadotropin treatment because of unexplained infertility or male subfertility after patent tubes had been diagnosed by hysterosalpingogram or laparoscopy (9) . Ovarian stimulation had been carried out with HP-FSH (Neo-Fertinorm; Serono S.A., Madrid, Spain) according to a late low-dose technique previously reported where obtaining unifollicular maturation is the goal (9) . Patients were given HP-FSH, 75 IU subcutaneously, from cycle day 7 until follicular maturation was reached. Transvaginal ultrasonography monitoring began on day 10 of the cycle, and it was carried out every other day until a dominant follicle of 14 mm or greater was identified; from that point daily controls were performed. An ovulatory triggering dose of 10,000 IU of human chorionic gonadotropin (hCG; Profasi; Serono S.A.) was used in all women when the leading follicle had reached a diameter of greater than 17 mm as shown by transvaginal ultrasonography monitoring.
Patients in group 2 (n = 20) had anovulatory infertility (WHO group II). They presented with oligomenorrhea or amenorrhea, the mean basal LH:FSH ratio was 2.5 ± 0.3 and the mean basal androstenedione level 283 ± 45 ng/dl, their mean body mass index was 24.2 ± 3.2, and all of them had the ultrasonographic appearance of polycystic ovaries (11) . An evident endogenous estrogen activity was shown in these patients by mean basal estradiol levels of 89.5 ± 8.5 pg/ml and a positive response to progestin challenge test (normal withdrawal bleeding after treatment with oral medroxyprogesterone acetate, 10 mg daily for 5 days) in each of them. The mean age of the patients in group 2 was 31 ± 0.8 years, and their mean duration of infertility was 3.8 ± 1.3 years. Normal male partner semen parameters, a normal hysterosalpingogram or laparoscopy, and no history of pelvic surgery and/or pelvic inflammatory disease were recorded previous to ovulation induction in these patients. All of them either had not ovulated with clomiphene citrate or had not conceived after at least three ovulatory cycles on this treatment at doses of 200 mg or less per day for 5 days. They were then treated with gonadotropins according to a low-dose protocol previously reported (8) .
Therapy with subcutaneous HP-FSH was commenced on days 2-4 of spontaneous cycle or of induced uterine bleeding. The regimen started with 75 IU HP-FSH daily for 7 days. If, however, the patient showed multiple follicular development on this dose, the dose was decreased to 37.5 IU of HP-FSH in the next cycle. The dose was increased by 0.5 ampoule (37.5 IU) every 7 days until there was evidence of active follicular development (follicle >10 mm in diameter). Once ovarian activity was seen on ultrasound, the same dose (i.e., the threshold dose) was continued until the follicular diameter was greater than 17 mm. hCG (Profasi; Serono S.A.), 10,000 IU intramuscularly, was then given to induce ovulation. All patients in group 2 had received three to six treatment cycles with HP-FSH according to this protocol, and all of them were ovulatory during the last gonadotropin treated cycle.
For the specific purposes of this study the last HP-FSH stimulated cycle in each woman in both study groups was compared with the subsequent gonadotropin treatment when subcutaneous rFSH (Gonal-F; Serono S.A.) was used in the same ovarian stimulation protocols described above. For each patient the starting FSH dose was identical in both treatment cycles; i.e, the same subcutaneous daily dose of FSH used during the first 3 (group 1) or 7 (group 2) treatment days in the last HP-FSH treated cycle was given in the rFSHstimulated cycle. Thus, each woman was her own control for ovarian performance and hormonal levels studies. The use of the same treatment protocol applied to different gonadotropin drugs in the same patient as previously done by us (12) and others (13, 14) seems the more appropriate study design when ovarian performance and hormonal levels, but not pregnancy rate, are the objectives to be compared.
For this study, plasma concentrations of both estradiol and inhibin A were measured retrospectively on the day of hCG injection in all treatment cycles studied. This was done using frozen plasma samples stored at -20°C, which were examined in one run. Hormones were measured using commercially available kits according to methods previously reported (15) (16) (17) . Estradiol plasma levels were estimated by direct radioimmunoassay (bioMerieux, Marcy 1'Etoile, France). The intraassay coefficient of variation was less than 4.5%. Inhibin A measurements were performed by a solid-phase sandwich enzyme-linked immunosorbent assay carried out in microtiter plates (Serotec Ltd., Oxford, England). The first monoclonal antibody, drycoated in the microwells, is specific for the PA subunit of inhibin, and the second is a monoclonal antibody specific for the a subunit labeled with alkaline phosphatase. The sample is incubated with the conjugated and then washed. Enzymatic activity of the enzyme retained is measured by spectrophotometry and the values obtained are interpolated in the standard curve (16, 17) . The assay sensitivity was 2 pg/ml, and the coefficient of variation within plate was less than 7%. The cross-reactivity with activin A was less than 0.1 %. Ultrasonic scans were performed with a 5-mHz vaginal transducer attached to an Aloka sector scanner (Model SSD-620; Aloka, Tokyo).
Data were analyzed by SPSS statistical software using the Wilcoxon matched-pairs signed-ranks test and the Pearson correlation coefficient as appropriate. Results are expressed as means with standard error and as medians and interquartile (25% and 75%) ranges. Significance was assumed at P < 0.05.
RESULTS
All gonadotropin-treated cycles included in the present study were ovulatory according to ultrasonographic evidence of ovulation (18), basal body temperature recording, and length of the luteal phase. There were one and two ongoing pregnancies in groups 1 and 2, respectively, with rFSH therapy. Comparative results of the two FSH treatment modalities in both study groups are summarized in Tables I and II. In group 1, there were no significant differences between both FSH treatments regarding the amount of FSH required for ovarian stimulation, the number and size of follicles on hCG day, and the hormonal Journal of Assisted Reproduction and Genetics, Vol. 15, No. 9, 1998 ovarian response as assessed by plasma estradiol and inhibin A concentrations on the day of hCG injection (Table I) .
On the contrary, in patients in group 2, the total quantity of FSH required to induce an identical follicular development was significantly lower in the rFSHtreated cycles compared with the HP-FSH therapy (Table II) . The median and range of the number of ampoules of gonadotropin used and days of gonadotropin treatment (Fig. 1) , as well as the mean threshold (daily effective) dose (Table II) , were also lower in the cycles of treament with rFSH. In contrast, plasma levels of both estradiol and inhibin A on the day of hCG administration were significantly higher in rFSH treatment cycles. When the study HP-FSH-treated cycles were compared with previous ovulation induction treatments received by patients in group 2 using the same urinary FSH preparation, no differences were found regarding treatment dosage and duration (data not shown).
For patients in group 2, a direct correlation was found between the basal LH:FSH ratio and both the number of ampules of FSH (r = 0.59; P < 0.05) and the days of gonadotropin treatment (r = 0.53; P < 0.05) when HP-FSH was used, but no correlation was evident between these parameters when rFSH treatment cycles were analyzed in the same group of patients. Similarly, basal androstenedione levels correlated directly with the number of ampoules (r = 0.85; P < 0.05) and days of ovarian stimulation (r = 0.92; 
P < 0.01) in HP-FSH but not rFSH-treated cycles.
In contrast, while estradiol plasma levels correlated directly with plasma concentrations of inhibin A on the hCG day for rFSH treatment cycles in patients with PCOS (r = 0.92; P < 0.01), such a correlation was lacking (r = 0.14; P = 0.7) when HP-FSH therapy was considered.
DISCUSSION
During the past decade, an important increase has occurred in the use of ovulation induction regimens, mainly those using gonadotropins. Gonadotropins are being used for treatment of both normally ovulating women undergoing assisted reproduction techniques and infertile patients with absent or inadequate ovulation. For years, gonadotropins obtained from urine of postmenopausal women and prepared as combinations of equivalent amounts of human urinary LH and human urinary FSH (human menopausal gonadotropin; hMG) have been the only preparations available for clinical use. Because of advances in the purification techniques that have become available over the past decade, human menopausal gonadotropin has been purified further.
In the early 1980s, pFSH was made possible by the development of affinity purification processes using polyvalent antibodies that yielded a relatively biologically pure FSH extract containing less than 1 IU of LH activity/75 IU FSH but still being contaminated with 95% of urinary proteins (19, 20) . The immunoextraction of urinary FSH using monoclonal antibodies has resulted in the clinical availability of HP-FSH containing less than 0.1 IU of LH activity/75 IU FSH and less than 5% of unidentified urinary proteins and which can be administered subcutaneously (20, 21) . Recently biotechnology has made available for the first time a recombinant human FSH preparation which has been and is being marketed in a number of countries. Because FSH needs to be glycosilated for biological activity, rFSH is produced by genetically engineered mammalian cells (Chinese hamster ovary cells), in which genes coding for the a and (3 FSH subunits have been inserted (22) . Only a mammalian cell can glycosylate the FSH protein correctly, thus ensuring full biological activity (23) . Recombinant LH (rLH) has also recently been made available for study, and the first pregnancy using rLH in combination with rFSH in a woman suffering from Kallmann syndrome was reported by Hull et al. (24) .
The use of molecularly pure forms of FSH and LH individually or in combination has led to a better understanding of the roles of FSH and LH in folliculogenesis and may have important clinical implications for the design of improved regimes to manipulate ovarian function (25) . In addition, there are data from IVF studies in patients undergoing gonadotropin ovarian stimulation under pituitary suppression with gonadotropin-releasing hormone (GnRH) agonists, suggesting a possible higher potency of rFSH compared with urinary FSH on the basis of the ovarian response obtained and the amount of FSH required (10, 26) .
Both in vitro studies (25) and clinical data (12) (13) (14) clearly indicate that FSH is the only factor required to induce follicular growth in the human, although LH may assist in achieving full follicular maturity and oocytes capable of fertilization. Therefore, WHO group I infertile women need both gonadotropins because they do not produce sufficient amounts of LH. However, there is general agreement that when endogenous LH is already elevated (e.g., in PCOS) pure FSH is conceptually better (19, 25) . The present study in which a highly purified preparation of urinary FSH and rFSH (i.e., molecularly pure FSH) were used in separate cycles in the same patients, adds new information to the subject.
All our patients in group 2 had polycystic ovaries on pelvic ultrasonography, and despite that there is no general agreement as to whether this technique is a kind of gold standard or whether endocrine and metabolic data should be favored over morphological findings, there is remarkable concordance between the results of studies wherein diagnoses have been based on ultrasonographic criteria and the results of those in which the PCOS has been defined on the basis of clinical and biochemical criteria (27, 28) . Therefore, it may be assumed that most of our patients in group 2 had polycystic ovaries. Our results indicate that both gonadotropin preparations are clinically useful but rFSH may have a higher in vivo biopotency compared with urinary FSH, which is evidenced mainly in those situations such as PCOS where intraovarian action of FSH is disrupted. The following facts support this contention. First, compared with urinary FSH, the total quantity of FSH required to induce follicular development in patients in group 2 was significantly lower with rFSH in a significantly shorter treatment period. Second, the mean threshold dose was significantly lower in rFSH treated cycles in such patients. In this respect, it is to be stressed that elevated serum LH and disturbed intraovarian regulation of FSH action are endocrine features in PCOS (29) , and early studies provided clinical evidence that the self-perpetuating state of biochemical imbalance so characteristic of PCOS could be interrupted in a physiologic way when "pure" pituitary FSH was administered in a chronic low dose (30) . Therefore, a third finding in our study supporting that contention is that a direct correlation was found between the basal LH:FSH ratio (and also the basal androstenedione level) and the treatment dosage and duration when HP-FSH was used, but this correlation was lacking in rFSH treatment cycles.
The fact that the treatment cycles in WHO group II anovulatory patients were almost identical with respect to follicular size and number on the day of hCG administration indicates that the stimulation procedures were carried out in a similar way. However, plasma levels of estradiol and inhibin A on the hCG day were significantly higher when rFSH was used in comparison with HP-FSH treatment. A very recent in vitro study has shown that granulosa cells from human ovarian follicles are highly responsive to rFSH, as demonstrated by increased steroid and inhibin production (31) . Also, a correlation between steroid and inhibin production was found in that study, thus indicating that the regulation of the synthesis and the secretion of these hormones are closely related (31) .
It should be noted that both estradiol and inhibin A are secreted from the granulosa cells and they are both indicators of follicular growth, recent work indicating that inhibin A may be the more reflective index of dominant follicle function and maturation (32) (33) (34) . There is a close relationship between FSH and inhibin A during the ovarian cycle, and inhibin may act within the ovary to promote follicular development (17, 32) . In fact, it has been shown that FSH-stimulated inhibin output by human granulosa cells can be enhanced by androgens but not by estrogens (35) . Nevertheless, estrogen can exert an indirect effect on inhibin synthesis through the stimulation of androgen synthesis in thecal cells (36) . In addition, inhibin produced by granulosa cells may act as a paracrine regulator to stimulate theca cell androgen production (37), which in turn provides substrate for estradiol synthesis by granulosa cells. Therefore, the direct correlation found in our study between estradiol and inhibin A plasma concentrations on the day of hCG administration in rFSHbut not HP-FSH-treated cycles is another argument favoring the better bioactive performance of rFSH compared with HP-FSH.
Previous studies in in vitro fertilization patients showed that inhibin and estradiol levels were highly correlated during ovarian stimulation with urinary gonadotropins (38) . However, those patients were nor-mal ovulatory women lacking the potential abnormal inhibin secretion reported as involved in PCOS (39) . In fact, impairment of folliculogenesis in women is associated with divergent responses in estradiol and inhibin production (38) . On the other hand, immunoreactive serum inhibin was measured in those early investigations (38) . Therefore, further studies including the recently available measurement of inhibin A are warranted in this regard.
There is no definite explanation for an increased bioactivity of rFSH compared with urofollitropins, but several hypotheses may be raised. First, calibration and assignment of gonadotropins biopotency is based on an in vivo bioassay (the Steelman-Pohley bioassay), which per se is rather insensitive and imprecise (inherent variation of 40%) and has a poor correlation with clinical response in humans (10, 19) . Gonadotropin preparations obtained with recombinant techniques and having constant isoform composition could be calibrated using a recombinant in vitro bioassay, eventually based on human gonadotropin receptors, which are very reliable, constant in their performance, and much more precise than traditional bioassays (19) . This would lead to more precise unitage assignment and to predictably lower individual variability with respect to the therapeutical response. On the contrary, minor differences of FSH isohormone profiles and considerable batch-to-batch variability in urinary preparations may result in a differential regulation of steroidogenesis and variations of circulating bioactive FSH actually stimulating the ovaries (29, 40) . Finally, other factors postulated to explain the higher biopotency of rFSH compared with urinary FSH include subtle differences in glycoform profile or the presence of proteinaceous contaminants in the urinary product inhibiting FSH action (10, 26, 41) .
It could be argued that the sequence of hormonal treatment in our patients could affect the study outcome. However, no differences were found regarding treatment dosage and duration when previous HP-FSH-treated cycles and the study cycle were compared in patients in group 2. Also, the use of pFSH, HP-FSH, or even rFSH has not been found to be superior to the use of human menopausal gonadotropin in terms of pregnancy rates after ovulation induction in patients with PCOS (6, 29, 42) . These were randomized studies where patients supposedly having the same endocrine abnormality received one of two treatments at random. However, PCOS is a heterogeneous condition with distinct endocrine features. Normal FSH serum levels in patients with PCOS suggest an elevated FSH threshold for stimulation of follicle growth. This FSH threshold varies for individual patients, thus suggesting variable ovarian abnormalities (29) . Therefore, as discussed above, the use of the same treatment protocol applied to different gonadotropin drugs in the same patient seems more appropriate when ovarian performance and hormonal levels, but not pregnancy rate, are the objectives to be compared (12) (13) (14) .
Finally, the lack of differences found in our study between the two gonadotropin treatments regarding total FSH dosage and ovarian response in group 1 patients does not invalidate our conclusion. This is in contrast with two recent studies showing that the use of rFSH for ovarian stimulation in in vitro fertilization is associated with higher levels of estradiol and a lower number of both FSH treatment days and number of ampoules of FSH used compared with urinary FSH (10, 26) . However, it should be noted that pituitaryovarian suppression was used in both studies where the multifollicular development was the goal. On the contrary, patients in group 1 in the present report were normal ovulatory women, having a normal LH:FSH ratio, and receiving FSH therapy for a short period only from cycle day 7 when the follicle destinate to ovulate has already been selected. This short-term, adjunctive therapy may explain why differences were found neither for total FSH dosage nor regarding estradiol and inhibin A levels when the two gonadotropin treatments were compared in patients in group 1.
In summary, this study has demonstrated that rFSH is more efficacious than urinary HP-FSH for ovulation induction in WHO group II anovulatory patients as assessed by ovarian performance, hormonal levels, and the amount of FSH required.
